share_log

Asymchem Laboratories (Tianjin) Co., Ltd. Recorded A 25% Miss On Revenue: Analysts Are Revisiting Their Models

Asymchem Laboratories (Tianjin) Co., Ltd. Recorded A 25% Miss On Revenue: Analysts Are Revisiting Their Models

Asymchem實驗室(天津)有限公司的收入下降了25%:分析師正在重新審視他們的模型
Simply Wall St ·  04/27 20:43

It's been a good week for Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) shareholders, because the company has just released its latest first-quarter results, and the shares gained 5.7% to CN¥80.99. Asymchem Laboratories (Tianjin) reported a serious miss, with revenue of CN¥1.4b falling a huge 25% short of analyst estimates. The bright side is that statutory earnings per share of CN¥6.26 were in line with forecasts. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

對於Asymchem實驗室(天津)有限公司(深圳證券交易所:002821)的股東來說,這是美好的一週,因爲該公司剛剛發佈了最新的第一季度業績,股價上漲了5.7%,至80.99元人民幣。Asymchem Laboratories(天津)報告了嚴重失誤,收入爲14億元人民幣,比分析師的預期大幅下降了25%。好的一面是,6.26元人民幣的法定每股收益符合預期。對於投資者來說,盈利是一個重要時刻,因爲他們可以追蹤公司的業績,查看分析師對明年的預測,看看對公司的情緒是否發生了變化。因此,我們收集了最新的業績後法定共識估計,以了解明年可能會發生什麼。

earnings-and-revenue-growth
SZSE:002821 Earnings and Revenue Growth April 28th 2024
SZSE: 002821 收益和收入增長 2024 年 4 月 28 日

Following the recent earnings report, the consensus from 16 analysts covering Asymchem Laboratories (Tianjin) is for revenues of CN¥6.45b in 2024. This implies a noticeable 7.5% decline in revenue compared to the last 12 months. Statutory earnings per share are forecast to plunge 38% to CN¥3.33 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥6.56b and earnings per share (EPS) of CN¥3.88 in 2024. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a real cut to EPS estimates.

繼最近的業績之後,涵蓋Asymchem實驗室(天津)的16位分析師一致認爲,2024年的收入爲64.5億元人民幣。這意味着與過去12個月相比,收入明顯下降了7.5%。預計同期法定每股收益將下降38%,至3.33元人民幣。然而,在最新業績公佈之前,分析師曾預計2024年的收入爲65.6億元人民幣,每股收益(EPS)爲3.88元人民幣。最新業績公佈後,分析師似乎變得更加看跌。儘管收入預測沒有變化,但每股收益的預期確實有所下調。

The average price target fell 13% to CN¥99.88, with reduced earnings forecasts clearly tied to a lower valuation estimate. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Asymchem Laboratories (Tianjin), with the most bullish analyst valuing it at CN¥145 and the most bearish at CN¥61.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

平均目標股價下降了13%,至99.88元人民幣,收益預期的下調顯然與估值估計值的降低有關。研究分析師的估計範圍,評估異常值與平均值的差異程度也可能很有啓發性。對Asymchem Laboratories(天津)的看法有所不同,最看漲的分析師將其估值爲145元人民幣,最看跌的爲每股61.00元人民幣。這是相當廣泛的估計,表明分析師正在預測該業務的各種可能結果。

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 9.8% by the end of 2024. This indicates a significant reduction from annual growth of 33% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 15% per year. It's pretty clear that Asymchem Laboratories (Tianjin)'s revenues are expected to perform substantially worse than the wider industry.

從現在的大局來看,我們可以理解這些預測的方法之一是看看它們如何與過去的業績和行業增長預期相比較。這些估計表明,收入預計將放緩,預計到2024年底年化下降9.8%。這表明與過去五年的33%的年增長率相比大幅下降。相比之下,我們的數據表明,總體而言,同一行業的其他公司的收入預計每年將增長15%。很明顯,Asymchem Laboratories(天津)的收入預計將大大低於整個行業。

The Bottom Line

底線

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Asymchem Laboratories (Tianjin). Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Asymchem Laboratories (Tianjin)'s revenue is expected to perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Asymchem Laboratories (Tianjin)'s future valuation.

最大的擔憂是,分析師下調了每股收益預期,這表明Asymchem Laboratories(天津)可能會面臨業務不利因素。幸運的是,分析師還重申了他們的收入預期,表明收入符合預期。儘管我們的數據確實表明,Asymchem Laboratories(天津)的收入預計將低於整個行業。共識目標股價大幅下降,分析師似乎沒有對最新結果感到放心,這導致對Asymchem Laboratories(天津)未來估值的估計降低。

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Asymchem Laboratories (Tianjin) going out to 2026, and you can see them free on our platform here..

根據這種思路,我們認爲該業務的長期前景比明年的收益重要得多。在Simply Wall St,我們有分析師對Asymchem Laboratories(天津)到2026年的全方位估計,你可以在我們的平台上免費看到這些估計。

Plus, you should also learn about the 1 warning sign we've spotted with Asymchem Laboratories (Tianjin) .

此外,您還應該了解我們在Asymchem實驗室(天津)發現的1個警告信號。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論